OBJECTIVE: Oxidized phospholipids (OxPLs) that are abundant in atherosclerotic lesions are increasingly recognized as context-dependent lipid mediators demonstrating both pro- and antiinflammatory activities. Molecular mechanisms of their effects are largely unknown. Here we present novel information on the mechanisms whereby OxPLs modulate activation of TLR4 by lipopolysaccharide (LPS). METHODS AND RESULTS: We show, using several cell types and various inflammatory genes as readouts, that different classes and molecular species of OxPLs do not stimulate TLR4 but exert prominent inhibitory effects on LPS-induced reactions. Our data demonstrate that binding of OxPLs to the LPS-binding protein (LBP) and CD14 prevents recognition of LPS by these proteins, thus impairing activation of TLR4. In addition, OxPLs inhibited LBP- and CD14-independent activation of TLR4 by the synthetic TLR4 agonist E6020 indicating that in parallel with LBP and CD14, OxPLs target cell-associated steps in TLR4 cascade. CONCLUSIONS: Our data suggest that OxPLs inhibit action of LPS via a multi-hit mechanism. These results support the notion that OxPLs are endogenous inhibitors of TLR4 produced in response to oxidative stress.
OBJECTIVE: Oxidized phospholipids (OxPLs) that are abundant in atherosclerotic lesions are increasingly recognized as context-dependent lipid mediators demonstrating both pro- and antiinflammatory activities. Molecular mechanisms of their effects are largely unknown. Here we present novel information on the mechanisms whereby OxPLs modulate activation of TLR4 by lipopolysaccharide (LPS). METHODS AND RESULTS: We show, using several cell types and various inflammatory genes as readouts, that different classes and molecular species of OxPLs do not stimulate TLR4 but exert prominent inhibitory effects on LPS-induced reactions. Our data demonstrate that binding of OxPLs to the LPS-binding protein (LBP) and CD14 prevents recognition of LPS by these proteins, thus impairing activation of TLR4. In addition, OxPLs inhibited LBP- and CD14-independent activation of TLR4 by the synthetic TLR4 agonist E6020 indicating that in parallel with LBP and CD14, OxPLs target cell-associated steps in TLR4 cascade. CONCLUSIONS: Our data suggest that OxPLs inhibit action of LPS via a multi-hit mechanism. These results support the notion that OxPLs are endogenous inhibitors of TLR4 produced in response to oxidative stress.
Authors: Cheng Luo; Xiangjun Yang; Angela D Kain; David W Powell; Markus H Kuehn; Gülgün Tezel Journal: Invest Ophthalmol Vis Sci Date: 2010-06-10 Impact factor: 4.799
Authors: Tobias Rothe; Florian Gruber; Stefan Uderhardt; Natacha Ipseiz; Susanne Rössner; Olga Oskolkova; Stephan Blüml; Norbert Leitinger; Wolfgang Bicker; Valery N Bochkov; Masayuki Yamamoto; Alexander Steinkasserer; Georg Schett; Elisabeth Zinser; Gerhard Krönke Journal: J Clin Invest Date: 2015-04-06 Impact factor: 14.808
Authors: Christoph L Baumann; Irene M Aspalter; Omar Sharif; Andreas Pichlmair; Stephan Blüml; Florian Grebien; Manuela Bruckner; Pawel Pasierbek; Karin Aumayr; Melanie Planyavsky; Keiryn L Bennett; Jacques Colinge; Sylvia Knapp; Giulio Superti-Furga Journal: J Exp Med Date: 2010-11-15 Impact factor: 14.307
Authors: Christopher P Thomas; Lloyd T Morgan; Benjamin H Maskrey; Robert C Murphy; Hartmut Kühn; Stanley L Hazen; Alison H Goodall; Hassan A Hamali; Peter W Collins; Valerie B O'Donnell Journal: J Biol Chem Date: 2010-01-08 Impact factor: 5.157